FDA Advisers Vote in Favor of Emergency Use Authorization for Moderna Vaccine for Ages 6-17

Yesterday, FDA vaccine advisers decided unanimously in favor of expanding the emergency use authorization of Moderna’s Covid-19 vaccine to include a second dose for children. All 22 members of the board voted on whether the benefits of the vaccine outweigh the risks to include older children and teens between the ages of 6 to 17. The FDA will now have to decide whether to authorize the vaccine for emergency use in the age group. The Pfizer/BioNTech Covid-19 vaccine is also already authorized for use as a booster in children as young as 5. The CDC’s vaccine advisers will now have to vote on whether to recommend the vaccine and Director Dr. Rochelle Walensky will have to sign off on the recommendation. Today, vaccine advisers are scheduled to meet to consider amending the emergency use authorization of Moderna’s vaccine to include children ages 6 months through 5 years. During the meeting they’ll also discuss amending the authorization of the Pfizer/ BioNTech vaccine to include ages 6 months through 4 years.